Skip to main content
      The Heartbreak of Sarcoidosis
      Airway Disease in GPA
      GLP-1 in Knee Osteoarthritis https://t.co/SxyVEAK1CZ

      @bella_mehta Discusses role of GLP1 in OA and possible mechanis

      Nouf Al hemmadi NoufAhmedAlham2

      1 week 3 days ago
      GLP-1 in Knee Osteoarthritis https://t.co/SxyVEAK1CZ @bella_mehta Discusses role of GLP1 in OA and possible mechanisms of effectiveness ? weight reduction ? or doses it have anti-inflammatory -anti-fibrotic role ? @RheumNow #ACR25
      Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb

      More on BiTES in SLE by the one and only @Yuz6Yusof

      Bi specific T

      Nouf Al hemmadi NoufAhmedAlham2

      1 week 3 days ago
      Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb More on BiTES in SLE by the one and only @Yuz6Yusof Bi specific Tcell engager ( CD3-CD19). @RheumNow #ACR25
      New Paradigms in RA Treatment https://t.co/CqpI2znglE

      @jeffsparks Highlights new trials in RA

      1-Neuro immune modulat

      Nouf Al hemmadi NoufAhmedAlham2

      1 week 3 days ago
      New Paradigms in RA Treatment https://t.co/CqpI2znglE @jeffsparks Highlights new trials in RA 1-Neuro immune modulation ( Vagal nerve stimulation). 2-Targeting pathogenic T cells 3-T reg CAR-T ( Peace maker). @RheumNow #ACR25
      Day 2 Recap: ACR Convergence 2025 Highlights https://t.co/b8XvrEsoLW

      Such a great time to be a rheumatologist.

      Fake r

      Nouf Al hemmadi NoufAhmedAlham2

      1 week 3 days ago
      Day 2 Recap: ACR Convergence 2025 Highlights https://t.co/b8XvrEsoLW Such a great time to be a rheumatologist. Fake rheumatology sounds like a great topic! Daily challenges and unusual presentations. @DrMiniDey @synovialjoints @drdavidliew @RheumNow #ACR25
      #ACR25 Abstr#0855 Five extra patients were added to complete IMPACT Open Label Phase 2 trial of add-on Certolizumab in A

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 3 days ago
      #ACR25 Abstr#0855 Five extra patients were added to complete IMPACT Open Label Phase 2 trial of add-on Certolizumab in APS women + LAC+ve. Results stood: primary endpoint was met (adverse pregnancy outcome=19.6%; lower than 20% expected). Significant enough to adopt @RheumNow https://t.co/zhFVGYXiaU
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      1 week 3 days ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      #ACR25 Day 1 RECAP

      Big takeaways, standout moments, and what set the tone for this year’s conference. We break down

      Dr. John Cush RheumNow

      1 week 3 days ago
      #ACR25 Day 1 RECAP Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1. https://t.co/js5FVBvUfk https://t.co/smh1AyPhfa
      Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.
      CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.
      A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.
      ×